Outcomes of Embryos Created From Abnormally Fertilized Oocytes
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Abnormal Fertilization, Infertility. Basic parameters: No limits · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The purpose of this study is to retrospectively analyze data from multiple clinics in a fertility network on embryos that were created from abnormally fertilized oocytes (AFO) including the rate of transfers and any clinical outcomes in order to inform providers in their decision making regarding AFOs.
Primary outcome measures
- Clinical Outcomes [Time frame: From embryo transfer to delivery]
Eligibility criteria
Inclusion criteria
- Underwent in vitro fertilization which resulted in a blastocyst derived from an abnormally fertilized embryo
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Publications
- Hondo S, Arichi A, Muramatsu H, Omura N, Ito K, Komine H, Monzen S, Mukai N, Endo M, Katase S, Kidera N, Sasaki H, Koi H, Yorimitsu T, Ohara M, Kawamura T, Shimizu Y. Clinical outcomes of transfer of frozen and thawed single blastocysts derived from nonpronuclear and monopronuclear zygotes. Reprod Med Biol. 2019 May 15;18(3):278-283. doi: 10.1002/rmb2.12275. eCollection 2019 Jul. PMID 31312107
- Kemper JM, Liu Y, Afnan M, Mol BWJ, Morbeck DE. What happens to abnormally fertilized embryos? A scoping review. Reprod Biomed Online. 2023 May;46(5):802-807. doi: 10.1016/j.rbmo.2023.02.005. Epub 2023 Feb 22. PMID 36997399
- Al Hashimi B, Harvey SC, Harvey KE, Linara-Demakakou E, Raikundalia B, Green O, Griffin DK, Ahuja K, Macklon N. Reassessing the conventional fertilization check: leveraging preimplantation genetic testing for aneuploidy to increase the number of transferrable embryos. Reprod Biomed Online. 2025 Jun;50(6):104595. doi: 10.1016/j.rbmo.2024.104595. Epub 2024 Oct 24. PMID 40262446
- Mutia K, Wiweko B, Iffanolida PA, Febri RR, Muna N, Riayati O, Jasirwan SO, Yuningsih T, Mansyur E, Hestiantoro A. The Frequency of Chromosomal Euploidy Among 3PN Embryos. J Reprod Infertil. 2019 Jul-Sep;20(3):127-131. PMID 31423415
- Girardi L, Patassini C, Miravet Valenciano J, Sato Y, Fagundes Cagnin N, Castellon JA, Cogo F, Zambon P, Blesa D, Jimenez Almazan J, Akinwole A, Coprerski B, Rubio C. Incidence of haploidy and triploidy in trophectoderm biopsies of blastocysts derived from normally and abnormally fertilized oocytes. J Assist Reprod Genet. 2024 Dec;41(12):3357-3370. doi: 10.1007/s10815-024-03278-4. Epub 2024 Oct 8. PMID 39378000
- Ezoe K, Takahashi T, Shimazaki K, Miki T, Tanimura Y, Amagai A, Sawado A, Akaike H, Mogi M, Kaneko S, Kato M, Kato K, Tarozzi N, Borini A, Coticchio G. Human 1PN and 3PN zygotes recapitulate all morphokinetic events of normal fertilization but reveal novel developmental errors. Hum Reprod. 2022 Sep 30;37(10):2307-2319. doi: 10.1093/humrep/deac177. PMID 35950593
- Canon C, Thurman A, Li A, Hernandez-Nieto C, Lee JA, Roth RM, Slifkin R, Briton-Jones C, Stein D, Copperman AB. Assessing the clinical viability of micro 3 pronuclei zygotes. J Assist Reprod Genet. 2023 Jul;40(7):1765-1772. doi: 10.1007/s10815-023-02830-y. Epub 2023 May 25. PMID 37227570
Identifiers
NCT: NCT07666243 · IRI-AFO-2026-001